Kinyanjui SM
26 results
Antibodies to PfEMP1 and Variant Surface Antigens: Protection after Controlled Human Malaria Infection in Semi-immune Kenyan Adults.Kinyua AW, Turner L, Kimingi HW, Mwai K, Mwikali K, Andisi C, Sim BKL, Bejon P, Kapulu MC, Kinyanjui SM, Lavstsen T, Abdi AI
J Infect, (2024). 89:106252
Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against Plasmodium falciparum parasites.Ogwang R, Murugu L, Nkumama IN, Nyamako L, Kai O, Mwai K, Murungi L, Idro R, Bejon P, Tuju J, Kinyanjui SM, Osier FHA
Front Immunol, (2024). 15:1360220
Antibody-Dependent Respiratory Burst against Plasmodium falciparum Merozoites in Individuals Living in an Area with Declining Malaria Transmission.Mutemi DD, Tuju J, Ogwang R, Nyamako L, Wambui KM, Cruz IR, Villner P, Yman V, Kinyanjui SM, Rooth I, Ngasala B, Färnert A, Osier FHA
Vaccines (Basel), (2024). 12:
Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.Kimingi HW, Kinyua AW, Achieng NA, Wambui KM, Mwangi S, Nguti R, Kivisi CA, Jensen ATR, Bejon P, Kapulu MC, Abdi AI, Kinyanjui SM, CHMI-SIKA Study Team
Front Immunol, (2022). 13:894770
The burden of neurological impairments and disability in older children measured in disability-adjusted life-years in rural Kenya.Abuga JA, Kariuki SM, Abubakar A, Kinyanjui SM, van Hensbroek MB, Newton CR
PLOS Glob Public Health, (2022). 2:e0000151
Neurological impairment and disability in children in rural Kenya.Abuga JA, Kariuki SM, Abubakar A, Nyundo C, Kinyanjui SM, Van Hensbroek MB, Newton CR
Dev Med Child Neurol, (2022). 64:347-356
Barriers to access and utilization of healthcare by children with neurological impairments and disability in low-and middle-income countries: a systematic review.Mwangi LW, Abuga JA, Cottrell E, Kariuki SM, Kinyanjui SM, Newton CR
Wellcome Open Res, (2021). 6:61
Tracking the introduction and spread of SARS-CoV-2 in coastal Kenya.Githinji G, de Laurent ZR, Mohammed KS, Omuoyo DO, Macharia PM, Morobe JM, Otieno E, Kinyanjui SM, Agweyu A, Maitha E, Kitole B, Suleiman T, Mwakinangu M, Nyambu J, Otieno J, Salim B, Kasera K, Kiiru J, Aman R, Barasa E, Warimwe G, Bejon P, Tsofa B, Ochola-Oyier LI, Nokes DJ, Agoti CN
Nat Commun, (2021). 12:4809
Premature Mortality, Risk Factors, and Causes of Death Following Childhood-Onset Neurological Impairments: A Systematic Review.Abuga JA, Kariuki SM, Kinyanjui SM, Boele van Hensbroek M, Newton CR
Front Neurol, (2021). 12:627824
Enhancing fieldworkers' performance management support in health research: an exploratory study on the views of field managers and fieldworkers from major research centres in Africa.Kombe FK, Marsh V, Molyneux S, Kamuya DM, Ikamba D, Kinyanjui SM
BMJ Open, (2019). 9:e028453
Premature mortality in children aged 6-9 years with neurological impairments in rural Kenya: a cohort study.Abuga JA, Kariuki SM, Kinyanjui SM, Boele Van Hensbroek M, Newton CR
Lancet Glob Health, (2019). 7:e1728-e1735
KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization.Kamuyu G, Tuju J, Kimathi R, Mwai K, Mburu J, Kibinge N, Chong Kwan M, Hawkings S, Yaa R, Chepsat E, Njunge JM, Chege T, Guleid F, Rosenkranz M, Kariuki CK, Frank R, Kinyanjui SM, Murungi LM, Bejon P, Farnert A, Tetteh KKA, Beeson JG, Conway DJ, Marsh K, Rayner JC, Osier FHA
Front Immunol, (2018). 9:2866
A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui SM, Marsh K, Osier FH
Vaccine, (2013). 31:3936-42
Strengthening the informed consent process in international health research through community engagement: The KEMRI-Wellcome Trust Research Programme Experience.Boga M, Davies A, Kamuya D, Kinyanjui SM, Kivaya E, Kombe F, Lang T, Marsh V, Mbete B, Mlamba A, Molyneux S, Mulupi S, Mwalukore S
PLoS Med, (2011). 8:e1001089
Effect of HIV infection on the acute antibody response to malaria antigens in children: an observational study.Muema DK, Ndungu FM, Kinyanjui SM, Berkley JA
Malar J, (2011). 10:55
What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity.Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K
Malar J, (2009). 8:242
Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure.Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, Bull PC, Marsh K
Infect Immun, (2009). 77:1917-23
Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children.Mackintosh CL, Mwangi T, Kinyanjui SM, Mosobo M, Pinches R, Williams TN, Newbold CI, Marsh K
Int J Parasitol, (2008). 38:1445-54
Evidence for over-dispersion in the distribution of clinical malaria episodes in children.Mwangi TW, Fegan G, Williams TN, Kinyanjui SM, Snow RW, Marsh K
PLoS One, (2008). 3:e2196
IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life.Kinyanjui SM, Conway DJ, Lanar DE, Marsh K
Malar J, (2007). 6:82